查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2003056

慢性骨髓性白血病治療市場：2026年至2032年全球市場預測（依治療方法、治療階段、作用機制、給藥途徑、劑型、患者年齡層、最終用戶和分銷管道分類）

Chronic Myelogenous Leukemia Therapeutics Market by Therapy Type, Treatment Line, Mechanism Of Action, Route Of Administration, Dosage Form, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，慢性骨髓性白血病(CML) 治療市場價值將達到 89 億美元，到 2026 年將成長至 95.9 億美元，到 2032 年將達到 152.9 億美元，複合年成長率為 8.02%。

主要市場統計數據
基準年 2025 89億美元
預計年份：2026年 95.9億美元
預測年份：2032年 152.9億美元
複合年成長率 (%) 8.02%

全面介紹慢性骨髓性白血病治療的現狀，包括不斷發展的臨床科學、監管重點和商業性趨勢。

本概要概述了慢性骨髓性白血病治療的現狀，整合了近期科學進展、不斷發展的臨床實踐以及支付方不斷變化的期望。過去十年，標靶治療重新定義了疾病控制目標、存活模式以及相關人員評估治療價值的指標。同時，監管機構調整了審查流程和證據要求，以平衡患者及時獲得治療與安全性要求，促使申辦方考慮採用適應性開發策略並儘早與相關人員溝通。

變革性變化分析：詳細了解正在重塑慢性骨髓性白血病。

隨著科學、臨床和數位化領域的融合，慢性骨髓性白血病的治療格局正在改變。分子診斷和精確分析的進步使得早期發現和更精細的風險分層成為可能，從而影響治療順序和監測強度。同時，蛋白酪氨酸激酶抑制劑和聯合治療的不斷改進正在改變人們對緩解期持續時間和耐受性的預期，使治療重點從短期療效轉向持續的生活品質和無治療期。

評估 2025 年美國關稅措施對 CML 治療供應鏈韌性、價格壓力和市場進入趨勢的累積影響。

2025年新關稅措施的實施將進一步提升全球醫藥供應鏈的營運彈性，這對於依賴海外採購的活性成分、特殊輔料和契約製造服務的藥物尤其重要。關稅導致投入成本和物流費用增加，將對價格談判、籌資策略和庫存政策產生影響，促使製造商重新評估其採購地點和供應商集中度風險。為此，許多公司優先考慮近岸外包、供應商多元化以及重新談判長期契約，以降低成本波動風險並維持獲利能力。

將綜合細分洞察（整合治療分類、治療線、作用機制、給藥途徑、最終用戶、分銷管道、劑型和患者群體）轉化為策略意義。

細分市場分析為慢性骨髓性白血病治療領域管線投資和商業化發展的優先排序提供了細緻的觀點。按治療方法類型分析市場，化療、合併療法和蛋白酪氨酸激酶抑制劑之間的差異帶來了不同的臨床和商業性挑戰。雖然諸如Busulfan、羥基脲和α干擾素等化療亞類在特定治療途徑中仍然發揮著重要作用，但蛋白酪氨酸激酶抑製劑與化療聯合或蛋白酪氨酸激酶抑製劑與單克隆抗體聯合的聯合療法，因其增強療效的潛力而日益受到重視。蛋白酪氨酸激酶抑制劑本身包括第一代、第二代和第三代藥物。Imatinib作為第一代藥物的代表，確立了聯合治療標靶治療的標竿；第二代藥物，包括Bosutinib、Dasatinib和尼洛替尼，在療效和抗藥性方面拓展了治療選擇；第三代藥物如Ponatinib則針對抗藥性或難治性病例。

美洲、歐洲、中東、非洲和亞太地區的區域趨勢和策略差異正在影響 CML 治療的可近性、報銷和臨床實施。

區域趨勢對慢性骨髓性白血病)治療方法的引進、進入和商業化策略有顯著影響。在美洲，儘管支付方結構較為分散，但頂級醫療中心眾多，且注重新藥的快速上市，因此更需要可靠的真實世界數據和早期准入項目。該地區的監管環境和報銷談判往往需要對市場進入計劃進行調整，並與支付方合作，以反映臨床實踐中的創新成果。

提供有關製藥創新者、非專利生產商、合約合作夥伴和戰略聯盟的企業和競爭信息，以推動 CML 治療的進步。

慢性骨髓性白血病)治療領域的競爭格局和企業發展趨勢，體現了成熟的創新製藥企業、靈活的生物技術公司和經驗豐富的非專利生產商之間的平衡，所有這些企業都得到了合約研發生產機構 (CDMO) 和專業服務供應商的支持。擁有豐富臨床產品組合的成熟研發公司通常專注於漸進式創新、生命週期管理和廣泛的實證醫學證據，以維持其長期的治療地位。相較之下，來自生技公司的新興企業則往往追求高影響力的差異化，透過全新的作用機制、獨特的聯合用藥策略或基於生物標記的適應症，旨在滿足未被滿足的醫療需求或克服抗藥性機制。

產業領導者為加強整個 CML 產品組合的研發優先性、供應鏈韌性、市場進入和病人參與採取的實用策略建議。

產業領導者可以將本報告中的洞見轉化為可執行的步驟，從而增強差異化優勢、降低業務風險並加速患者獲得治療。首先，應優先制定整合精準診斷和生物標記主導臨床實驗設計的研發策略，以最佳化反應患者的核准並支持強力的適應症聲明。同時，應將真實世界證據的收集納入上市前和核准後的規劃，以滿足支付方的要求並展現長期價值。從營運角度來看，應實現供應商網路多元化並探索近岸外包機會，以降低貿易政策波動和物流瓶頸帶來的風險，同時確保產品品質和合規性。

這項 CML 分析基於高度透明的調查方法，詳細說明了來自一級和二級調查的研究證據的三角驗證、專家檢驗和品質保證流程。

本分析的調查方法是基於系統性地結合一手和二手研究，旨在確保研究的嚴謹性、透明度和相關性。一手研究包括對臨床醫生、支付方顧問、監管專家和商業領域領導者的定向訪談，以及與生產和分銷專家的定性討論，以了解實際情況。二手研究則利用同儕審查文獻、臨床實驗室註冊數據、監管指導文件和公開的衛生技術評估，整合歷史趨勢並將其與當前的策略考量聯繫起來。

權威的綜合分析報告，重點闡述了策略轉折點、持續存在的挑戰以及將塑造 CML 治療未來發展軌蹟的切實機會。

總之，慢性骨髓性白血病治療正處於一個戰略轉折點，分子層面認知的加深、治療方法創新的迭代以及新型護理模式的交匯融合，為行業相關人員帶來了機會和責任。抗藥性機制、公平取得藥物以及實證醫學證據的累積等持續存在的挑戰依然突出，但也為透過聯合治療、生物標記開發和完善的患者支持體系實現差異化提供了清晰的路徑。供應鏈趨勢、不斷變化的監管環境以及支付方的期望之間的相互作用，進一步凸顯了從藥物研發到交付進行整合規劃的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：慢性骨髓性白血病治療市場：依治療方法

  • 化療
    • Busulfan
    • 羥基脲
    • α干擾素
  • 聯合治療
    • 蛋白酪氨酸激酶抑制劑與化療合併使用
    • 單株抗體組合蛋白酪氨酸激酶抑制劑
  • 蛋白酪氨酸激酶抑制劑
    • 第一代
    • 第二代
      • Bosutinib
      • Dasatinib
      • 尼洛替尼
    • 第三代

第9章：慢性骨髓性白血病治療市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第10章：慢性骨髓性白血病治療市場：依作用機制分類

  • 化療
  • 同時用藥
  • 蛋白酪氨酸激酶抑制

第11章慢性骨髓性白血病治療市場：依給藥途徑分類

  • 口服
  • 腸外
    • 靜脈
    • 皮下

第12章慢性骨髓性白血病治療市場：依劑型分類

  • 膠囊
  • 注射藥物
  • 注射用粉劑
  • 藥片

第13章慢性骨髓性白血病治療市場：依患者年齡層分類

  • 成年患者
  • 老年患者
  • 兒童患者

第14章慢性骨髓性白血病治療市場：依最終用戶分類

  • 診所
  • 居家照護設施
  • 醫院
  • 專業醫療中心

第15章：慢性骨髓性白血病治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第16章慢性骨髓性白血病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章慢性骨髓性白血病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章慢性骨髓性白血病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國慢性骨髓性白血病治療市場

第20章：中國慢性骨髓性白血病治療市場。

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Ascentage Pharma Group International Co., Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hansoh Pharmaceutical Group Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Ilyang Pharmaceutical Co., Ltd.
  • Innovent Biologics, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Rasna Therapeutics, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-957C47F953D7

The Chronic Myelogenous Leukemia Therapeutics Market was valued at USD 8.90 billion in 2025 and is projected to grow to USD 9.59 billion in 2026, with a CAGR of 8.02%, reaching USD 15.29 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.90 billion
Estimated Year [2026] USD 9.59 billion
Forecast Year [2032] USD 15.29 billion
CAGR (%) 8.02%

Comprehensive introduction framing the evolving clinical science regulatory priorities and commercial dynamics now defining chronic myelogenous leukemia therapeutics

This executive introduction frames the contemporary contours of chronic myelogenous leukemia therapeutics by synthesizing recent scientific advances with shifting clinical practices and evolving payer expectations. Over the past decade, targeted therapies have redefined disease control objectives, survival paradigms, and the metrics stakeholders use to evaluate therapeutic value. In parallel, regulatory agencies have adapted review pathways and evidence requirements to balance timely patient access with safety imperatives, prompting sponsors to consider adaptive development strategies and earlier stakeholder engagement.

Consequently, commercial and operational leaders face a complex landscape in which clinical differentiation, real-world evidence generation, and supply chain resilience converge as imperative priorities. This introduction establishes the foundation for the subsequent analysis by identifying the core forces shaping research priorities, clinical adoption, and patient support models. By clarifying the interplay among scientific innovation, regulatory trajectories, and commercial execution, the section prepares decision-makers to interpret the deeper insights and recommendations presented in the following sections.

Transformative shifts analysis detailing scientific breakthroughs therapeutic paradigms and patient centric care models that are reshaping chronic myelogenous leukemia treatment pathways

The therapeutic landscape for chronic myelogenous leukemia is undergoing transformative shifts driven by converging scientific, clinical, and digital forces. Advances in molecular diagnostics and precision profiling have enabled earlier detection and more granular risk stratification, which in turn influence treatment sequencing and monitoring intensity. Concurrently, iterative improvements in tyrosine kinase inhibitors and combination regimens have altered expectations around remission durability and tolerability, shifting the emphasis from short-term response to sustained quality of life and treatment-free intervals.

In addition to therapeutic innovation, patient-centric care models and decentralized clinical pathways are reshaping how treatments are delivered and monitored. Remote monitoring technologies, telehealth-enabled consultations, and home-based administration require sponsors and providers to redesign support services and adherence programs. Moreover, regulatory authorities and payers increasingly demand robust real-world evidence and health economics data to inform reimbursement decisions, prompting cross-functional alignment between clinical development teams and value demonstration functions. Together, these shifts create both opportunities and complexities for stakeholders seeking to differentiate portfolios and demonstrate long-term clinical and economic value.

Assessment of the cumulative effects of United States tariff measures in 2025 on supply chain resilience pricing pressures and commercial access dynamics for CML therapeutics

The introduction of new tariff measures in 2025 has amplified the need for operational agility across global pharmaceutical supply chains, with particular relevance for therapies that rely on internationally sourced active pharmaceutical ingredients, specialized excipients, and contract manufacturing services. Tariff-induced increases in input costs and logistics expenses can propagate through pricing discussions, procurement strategies, and inventory policies, prompting manufacturers to reassess sourcing footprints and supplier concentration risks. In response, many organizations are prioritizing nearshoring, diversifying supplier bases, and renegotiating long-term agreements to mitigate cost volatility and preserve margin structure.

Beyond procurement, tariffs exert indirect effects on market access dialogues and payer negotiations. Higher production and distribution costs can complicate price discussions, especially in markets where reimbursement frameworks are tightly constrained. To preserve affordability while maintaining commercial viability, companies are increasingly combining cost-management tactics with evidence-based value propositions that emphasize long-term clinical and economic benefits. As a result, cross-functional teams must integrate trade-policy scenario planning into development timelines and commercial launch readiness, ensuring that regulatory submissions, pricing strategies, and patient access programs remain robust under multiple tariff and supply-chain contingencies.

Holistic segmentation insights integrating therapy classes treatment lines mechanisms routes end users distribution channels formulations and patient cohorts into strategic implications

Segment-level analysis provides a nuanced lens through which to prioritize pipeline investments and commercial deployment for chronic myelogenous leukemia therapeutics. When viewing the market by therapy type, distinctions between chemotherapy, combination agents, and tyrosine kinase inhibitors create different clinical and commercial imperatives. Chemotherapy subsegments such as busulfan, hydroxyurea, and interferon alfa continue to play defined roles in select care pathways, while combination agents that pair a tyrosine kinase inhibitor with chemotherapy or a tyrosine kinase inhibitor with a monoclonal antibody are increasingly evaluated for their potential to deepen responses. Tyrosine kinase inhibitors themselves span first, second, and third generation agents; the first generation example imatinib established the targeted therapy benchmark, second generation agents including bosutinib, dasatinib, and nilotinib expanded options around potency and resistance profiles, and third generation agents such as ponatinib are positioned for resistant or refractory settings.

In terms of treatment line segmentation, clear differences emerge between first-line use, second-line transitions, and third-line and beyond, each demanding distinct evidence sets and patient support mechanisms. Mechanism of action breakdowns mirror therapy-type distinctions and influence safety monitoring, combination potential, and clinical trial design. Route of administration considerations bifurcate between oral regimens and parenteral delivery, the latter further differentiated into intravenous and subcutaneous options and carrying implications for site-of-care planning. End user segmentation spans clinics, home care settings, hospitals, and specialty centers, which shapes distribution strategies and patient support services. Distribution channels encompass hospital pharmacies, online pharmacies, and retail pharmacies and require tailored logistics and contracting approaches. Dosage forms such as capsules, injections, powder for injection, and tablets influence patient adherence and manufacturing choices. Finally, patient age group segmentation across adult, geriatric, and pediatric cohorts imposes distinct safety, dosing, and patient engagement considerations that must be integrated into development plans and commercial strategies.

Regional dynamics and strategic variations across the Americas Europe Middle East and Africa and Asia Pacific shaping access reimbursement and clinical adoption in CML care

Regional dynamics materially influence therapeutic adoption, access, and commercialization strategies for chronic myelogenous leukemia. In the Americas, fragmented payer landscapes coexist with centers of excellence and an emphasis on rapid uptake of novel agents, driving the need for robust real-world evidence and early access programs. Regulatory processes and reimbursement negotiations in this region frequently require coordinated market access planning and payer engagement to translate clinical innovation into routine practice.

Across Europe, Middle East and Africa, heterogeneity in regulatory frameworks, reimbursement mechanisms, and healthcare infrastructure demands flexible market entry approaches. Countries within this geography differ markedly in pricing transparency, tendering practices, and the availability of specialist care, which compels manufacturers to adopt differentiated value dossiers and localized engagement strategies. In the Asia-Pacific region, rapid adoption of targeted therapies in advanced care centers sits alongside varied access in emerging markets; strategic partnerships, local manufacturing, and capacity building can accelerate reach. Taken together, these regional contrasts necessitate tailored commercialization plans that reconcile global development objectives with localized operational execution, payer dialogues, and clinician education initiatives.

Corporate and competitive intelligence examining pharmaceutical innovators generics manufacturers contract partners and strategic alliances driving CML therapeutic advancement

Competitive and corporate dynamics in the chronic myelogenous leukemia therapeutic space reflect a balance between established pharmaceutical innovators, agile biotechnology firms, and experienced generic manufacturers, all supported by contract development and manufacturing organizations and specialty service providers. Established developers with deep clinical portfolios often focus on incremental innovation, lifecycle management, and broad evidence generation to sustain long-term therapy positioning. Biotech entrants, by contrast, frequently pursue high-impact differentiation through novel mechanisms, unique combination strategies, or biomarker-driven indications that aim to solve unmet clinical needs or overcome resistance mechanisms.

Meanwhile, manufacturers that specialize in generics and biosimilars can exert downward pressure on pricing while expanding access in cost-constrained settings, which compels originators to emphasize differentiation through patient support services and outcomes data. Contract organizations and specialty pharmacies play a pivotal enabling role by scaling production, ensuring regulatory compliance, and supporting complex distribution and adherence programs. Across these profiles, strategic alliances, licensing deals, and targeted acquisitions remain key mechanisms for gaining technical capabilities, geographic reach, and late-stage assets that accelerate time to market and broaden therapeutic portfolios.

Actionable strategic recommendations for industry leaders to enhance R&D prioritization supply chain resilience market access and patient engagement across CML portfolios

Industry leaders can translate the insights in this report into practical actions that strengthen differentiation, mitigate operational risk, and accelerate patient access. To begin, prioritize development strategies that integrate precision diagnostics and biomarker-driven trial designs to optimize responder identification and support compelling label claims. Simultaneously, embed real-world evidence generation into both pre- and post-approval plans to satisfy payer requirements and demonstrate long-term value. From an operational perspective, diversify supplier networks and explore nearshoring opportunities to reduce exposure to trade-policy shocks and logistic bottlenecks while maintaining quality and regulatory compliance.

Commercially, align pricing and access strategies with evidence-based health economic models and design patient support programs that address adherence, monitoring, and treatment transitions across settings of care. Invest in digital engagement and remote monitoring capabilities to support decentralized care models and to collect real-world endpoints that matter to clinicians and payers. Pursue strategic partnerships with regional stakeholders to accelerate market entry and tailor commercialization approaches to local reimbursement environments. Finally, establish cross-functional governance that brings together R&D, regulatory, market access, and commercial teams to ensure coherent decision-making and rapid response to evolving clinical and policy signals.

Transparent research methodology detailing primary and secondary research evidence triangulation expert validation and quality assurance processes underlying this CML analysis

The research methodology underpinning this analysis rests on a structured combination of primary and secondary approaches designed to ensure rigor, transparency, and relevance. Primary research included targeted interviews with clinicians, payer advisors, regulatory experts, and commercial leaders, alongside qualitative discussions with manufacturing and distribution specialists to capture operational realities. Secondary research drew on peer-reviewed literature, clinical trial registries, regulatory guidance documents, and publicly available health technology assessments to synthesize historical trends and link them to present-day strategic considerations.

Data triangulation was applied to reconcile findings across sources, and thematic analysis was used to surface recurrent opportunities and risks. Quality assurance steps included expert validation rounds and internal peer review to corroborate interpretations and to identify potential bias. Limitations are acknowledged where evidence remains emergent or regionally heterogeneous, and assumptions are clearly stated within the report narrative. The methodology emphasizes reproducibility and notes pathways for future updates as new clinical data, policy developments, or commercial results become available.

Conclusive synthesis highlighting strategic inflection points persistent challenges and pragmatic opportunities shaping the future trajectory of CML therapeutics

In conclusion, chronic myelogenous leukemia therapeutics occupy a strategic inflection point where refined molecular understanding, iterative therapeutic innovation, and new models of care converge to create both opportunities and obligations for industry stakeholders. Persistent challenges around resistance mechanisms, equitable access, and evidence generation remain salient, yet they also present clear pathways for differentiation through combination strategies, biomarker development, and enhanced patient support systems. The interplay of supply-chain dynamics, regulatory evolution, and payer expectations further underscores the need for integrated planning that spans from discovery to delivery.

Ultimately, organizations that harmonize clinical development with robust real-world evidence generation, resilient operational architectures, and tailored regional commercialization will be better positioned to deliver durable patient outcomes and sustainable business performance. The strategic priorities identified here can guide cross-functional investments and partnerships that reconcile scientific promise with commercial feasibility, thereby enabling therapies to reach the patients who stand to benefit most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Myelogenous Leukemia Therapeutics Market, by Therapy Type

  • 8.1. Chemotherapy
    • 8.1.1. Busulfan
    • 8.1.2. Hydroxyurea
    • 8.1.3. Interferon Alfa
  • 8.2. Combination Agents
    • 8.2.1. Tyrosine Kinase Inhibitor With Chemotherapy
    • 8.2.2. Tyrosine Kinase Inhibitor With Monoclonal Antibody
  • 8.3. Tyrosine Kinase Inhibitors
    • 8.3.1. First Generation
    • 8.3.2. Second Generation
      • 8.3.2.1. Bosutinib
      • 8.3.2.2. Dasatinib
      • 8.3.2.3. Nilotinib
    • 8.3.3. Third Generation

9. Chronic Myelogenous Leukemia Therapeutics Market, by Treatment Line

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line And Beyond

10. Chronic Myelogenous Leukemia Therapeutics Market, by Mechanism Of Action

  • 10.1. Chemotherapy
  • 10.2. Combination Agents
  • 10.3. Tyrosine Kinase Inhibition

11. Chronic Myelogenous Leukemia Therapeutics Market, by Route Of Administration

  • 11.1. Oral
  • 11.2. Parenteral
    • 11.2.1. Intravenous
    • 11.2.2. Subcutaneous

12. Chronic Myelogenous Leukemia Therapeutics Market, by Dosage Form

  • 12.1. Capsule
  • 12.2. Injection
  • 12.3. Powder For Injection
  • 12.4. Tablet

13. Chronic Myelogenous Leukemia Therapeutics Market, by Patient Age Group

  • 13.1. Adult Patients
  • 13.2. Geriatric Patients
  • 13.3. Pediatric Patients

14. Chronic Myelogenous Leukemia Therapeutics Market, by End User

  • 14.1. Clinics
  • 14.2. Home Care Settings
  • 14.3. Hospitals
  • 14.4. Specialty Centers

15. Chronic Myelogenous Leukemia Therapeutics Market, by Distribution Channel

  • 15.1. Hospital Pharmacies
  • 15.2. Online Pharmacies
  • 15.3. Retail Pharmacies

16. Chronic Myelogenous Leukemia Therapeutics Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Chronic Myelogenous Leukemia Therapeutics Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Chronic Myelogenous Leukemia Therapeutics Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Chronic Myelogenous Leukemia Therapeutics Market

20. China Chronic Myelogenous Leukemia Therapeutics Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AbbVie Inc.
  • 21.6. Agios Pharmaceuticals, Inc.
  • 21.7. Amgen Inc.
  • 21.8. Amneal Pharmaceuticals, Inc.
  • 21.9. Ascentage Pharma Group International Co., Ltd.
  • 21.10. Astellas Pharma Inc.
  • 21.11. AstraZeneca PLC
  • 21.12. Aurobindo Pharma Limited
  • 21.13. Bayer AG
  • 21.14. Bristol-Myers Squibb Company
  • 21.15. Cipla Limited
  • 21.16. Dr. Reddy's Laboratories Ltd
  • 21.17. F. Hoffmann-La Roche Ltd.
  • 21.18. GlaxoSmithKline plc
  • 21.19. Hansoh Pharmaceutical Group Co., Ltd.
  • 21.20. Hikma Pharmaceuticals PLC
  • 21.21. Ilyang Pharmaceutical Co., Ltd.
  • 21.22. Innovent Biologics, Inc.
  • 21.23. Johnson & Johnson Services, Inc.
  • 21.24. Lupin Limited
  • 21.25. Merck & Co., Inc.
  • 21.26. Novartis AG
  • 21.27. Otsuka Holdings Co., Ltd.
  • 21.28. Pfizer Inc.
  • 21.29. Rasna Therapeutics, Inc.
  • 21.30. Sanofi S.A.
  • 21.31. Sun Pharmaceutical Industries Limited
  • 21.32. Takeda Pharmaceutical Company Limited
  • 21.33. Teva Pharmaceutical Industries Ltd.
  • 21.34. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BUSULFAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BUSULFAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BUSULFAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HYDROXYUREA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HYDROXYUREA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTERFERON ALFA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTERFERON ALFA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTERFERON ALFA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY POWDER FOR INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY POWDER FOR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY POWDER FOR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 262. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 263. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 264. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)

TABLE